287 related articles for article (PubMed ID: 37545504)
1. Targeted degradation of MERTK and other TAM receptor paralogs by heterobifunctional targeted protein degraders.
Gadiyar V; Patel G; Chen J; Vigil D; Ji N; Campbell V; Sharma K; Shi Y; Weiss MM; Birge RB; Davra V
Front Immunol; 2023; 14():1135373. PubMed ID: 37545504
[TBL] [Abstract][Full Text] [Related]
2. Receptor tyrosine kinases Tyro3, Axl, and Mertk differentially contribute to antibody-induced arthritis.
Gao L; He C; Yang A; Zhou H; Lu Q; Birge RB; Wu Y
Cell Commun Signal; 2023 Aug; 21(1):195. PubMed ID: 37537628
[TBL] [Abstract][Full Text] [Related]
3. Axl and Mertk Receptors Cooperate to Promote Breast Cancer Progression by Combined Oncogenic Signaling and Evasion of Host Antitumor Immunity.
Davra V; Kumar S; Geng K; Calianese D; Mehta D; Gadiyar V; Kasikara C; Lahey KC; Chang YJ; Wichroski M; Gao C; De Lorenzo MS; Kotenko SV; Bergsbaken T; Mishra PK; Gause WC; Quigley M; Spires TE; Birge RB
Cancer Res; 2021 Feb; 81(3):698-712. PubMed ID: 33239426
[TBL] [Abstract][Full Text] [Related]
4. Tyro3, Axl, and Mertk receptors differentially participate in platelet activation and thrombus formation.
Zhou J; Yang A; Wang Y; Chen F; Zhao Z; Davra V; Suzuki-Inoue K; Ozaki Y; Birge RB; Lu Q; Wu Y
Cell Commun Signal; 2018 Dec; 16(1):98. PubMed ID: 30541554
[TBL] [Abstract][Full Text] [Related]
5. MERTK Mediates Intrinsic and Adaptive Resistance to AXL-targeting Agents.
McDaniel NK; Cummings CT; Iida M; Hülse J; Pearson HE; Vasileiadi E; Parker RE; Orbuch RA; Ondracek OJ; Welke NB; Kang GH; Davies KD; Wang X; Frye SV; Earp HS; Harari PM; Kimple RJ; DeRyckere D; Graham DK; Wheeler DL
Mol Cancer Ther; 2018 Nov; 17(11):2297-2308. PubMed ID: 30093568
[TBL] [Abstract][Full Text] [Related]
6. Targeting Tyro3, Axl and MerTK (TAM receptors): implications for macrophages in the tumor microenvironment.
Myers KV; Amend SR; Pienta KJ
Mol Cancer; 2019 May; 18(1):94. PubMed ID: 31088471
[TBL] [Abstract][Full Text] [Related]
7. Axl and MerTK receptor tyrosine kinases maintain human macrophage efferocytic capacity in the presence of viral triggers.
Grabiec AM; Goenka A; Fife ME; Fujimori T; Hussell T
Eur J Immunol; 2018 May; 48(5):855-860. PubMed ID: 29400409
[TBL] [Abstract][Full Text] [Related]
8. Phosphatidylserine Sensing by TAM Receptors Regulates AKT-Dependent Chemoresistance and PD-L1 Expression.
Kasikara C; Kumar S; Kimani S; Tsou WI; Geng K; Davra V; Sriram G; Devoe C; Nguyen KN; Antes A; Krantz A; Rymarczyk G; Wilczynski A; Empig C; Freimark B; Gray M; Schlunegger K; Hutchins J; Kotenko SV; Birge RB
Mol Cancer Res; 2017 Jun; 15(6):753-764. PubMed ID: 28184013
[TBL] [Abstract][Full Text] [Related]
9. TAM Family Receptor Kinase Inhibition Reverses MDSC-Mediated Suppression and Augments Anti-PD-1 Therapy in Melanoma.
Holtzhausen A; Harris W; Ubil E; Hunter DM; Zhao J; Zhang Y; Zhang D; Liu Q; Wang X; Graham DK; Frye SV; Earp HS
Cancer Immunol Res; 2019 Oct; 7(10):1672-1686. PubMed ID: 31451482
[TBL] [Abstract][Full Text] [Related]
10. Antagonistic Coevolution of MER Tyrosine Kinase Expression and Function.
Evans AL; Blackburn JWD; Taruc K; Kipp A; Dirk BS; Hunt NR; Barr SD; Dikeakos JD; Heit B
Mol Biol Evol; 2017 Jul; 34(7):1613-1628. PubMed ID: 28369510
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of MERTK receptor tyrosine kinase in epithelial cancer cells drives efferocytosis in a gain-of-function capacity.
Nguyen KQ; Tsou WI; Calarese DA; Kimani SG; Singh S; Hsieh S; Liu Y; Lu B; Wu Y; Garforth SJ; Almo SC; Kotenko SV; Birge RB
J Biol Chem; 2014 Sep; 289(37):25737-49. PubMed ID: 25074939
[TBL] [Abstract][Full Text] [Related]
12. Small molecule inhibitors block Gas6-inducible TAM activation and tumorigenicity.
Kimani SG; Kumar S; Bansal N; Singh K; Kholodovych V; Comollo T; Peng Y; Kotenko SV; Sarafianos SG; Bertino JR; Welsh WJ; Birge RB
Sci Rep; 2017 Mar; 7():43908. PubMed ID: 28272423
[TBL] [Abstract][Full Text] [Related]
13. The small-molecule MERTK inhibitor UNC2025 decreases platelet activation and prevents thrombosis.
Branchford BR; Stalker TJ; Law L; Acevedo G; Sather S; Brzezinski C; Wilson KM; Minson K; Lee-Sherick AB; Davizon-Castillo P; Ng C; Zhang W; Neeves KB; Lentz SR; Wang X; Frye SV; Shelton Earp H; DeRyckere D; Brass LF; Graham DK; Di Paola JA
J Thromb Haemost; 2018 Feb; 16(2):352-363. PubMed ID: 29045015
[TBL] [Abstract][Full Text] [Related]
14. Normalization of TAM post-receptor signaling reveals a cell invasive signature for Axl tyrosine kinase.
Kimani SG; Kumar S; Davra V; Chang YJ; Kasikara C; Geng K; Tsou WI; Wang S; Hoque M; Boháč A; Lewis-Antes A; De Lorenzo MS; Kotenko SV; Birge RB
Cell Commun Signal; 2016 Sep; 14(1):19. PubMed ID: 27595981
[TBL] [Abstract][Full Text] [Related]
15. TAM-ing T cells in the tumor microenvironment: implications for TAM receptor targeting.
Peeters MJW; Rahbech A; Thor Straten P
Cancer Immunol Immunother; 2020 Feb; 69(2):237-244. PubMed ID: 31664482
[TBL] [Abstract][Full Text] [Related]
16. Macrophage AXL receptor tyrosine kinase inflames the heart after reperfused myocardial infarction.
DeBerge M; Glinton K; Subramanian M; Wilsbacher LD; Rothlin CV; Tabas I; Thorp EB
J Clin Invest; 2021 Mar; 131(6):. PubMed ID: 33529176
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic targeting of the functionally elusive TAM receptor family.
Miao YR; Rankin EB; Giaccia AJ
Nat Rev Drug Discov; 2024 Mar; 23(3):201-217. PubMed ID: 38092952
[TBL] [Abstract][Full Text] [Related]
18. Receptor tyrosine kinases, TYRO3, AXL, and MER, demonstrate distinct patterns and complex regulation of ligand-induced activation.
Tsou WI; Nguyen KQ; Calarese DA; Garforth SJ; Antes AL; Smirnov SV; Almo SC; Birge RB; Kotenko SV
J Biol Chem; 2014 Sep; 289(37):25750-63. PubMed ID: 25074926
[TBL] [Abstract][Full Text] [Related]
19. Macrophages and dendritic cells use different Axl/Mertk/Tyro3 receptors in clearance of apoptotic cells.
Seitz HM; Camenisch TD; Lemke G; Earp HS; Matsushima GK
J Immunol; 2007 May; 178(9):5635-42. PubMed ID: 17442946
[TBL] [Abstract][Full Text] [Related]
20. Mertk: An emerging target in cancer biology and immuno-oncology.
Lahey KC; Gadiyar V; Hill A; Desind S; Wang Z; Davra V; Patel R; Zaman A; Calianese D; Birge RB
Int Rev Cell Mol Biol; 2022; 368():35-59. PubMed ID: 35636929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]